Zacks Research Downgrades Eupraxia Pharmaceuticals (NASDAQ:EPRX) to Strong Sell

Eupraxia Pharmaceuticals (NASDAQ:EPRX) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Tuesday,Zacks.com reports.

EPRX has been the topic of a number of other research reports. HC Wainwright dropped their price target on Eupraxia Pharmaceuticals from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday. Cantor Fitzgerald lifted their price objective on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday, January 15th. Wall Street Zen cut Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Lifesci Capital raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Eupraxia Pharmaceuticals Trading Down 0.9%

NASDAQ:EPRX opened at $7.51 on Tuesday. Eupraxia Pharmaceuticals has a 12 month low of $2.68 and a 12 month high of $9.32. The firm’s 50 day moving average is $8.30 and its 200 day moving average is $6.87. The stock has a market capitalization of $270.06 million, a PE ratio of -7.29 and a beta of 1.27.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its quarterly earnings data on Thursday, March 19th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.21). Research analysts predict that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current year.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Several hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd purchased a new stake in Eupraxia Pharmaceuticals during the 4th quarter worth about $122,000. Ikarian Capital LLC purchased a new position in Eupraxia Pharmaceuticals during the 4th quarter valued at about $4,606,000. Squadron Capital Management LLC bought a new stake in shares of Eupraxia Pharmaceuticals during the fourth quarter valued at about $3,775,000. SummitTX Capital L.P. bought a new stake in shares of Eupraxia Pharmaceuticals during the fourth quarter valued at about $1,328,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Eupraxia Pharmaceuticals in the fourth quarter worth about $326,000.

Key Eupraxia Pharmaceuticals News

Here are the key news stories impacting Eupraxia Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintains a “Buy” rating and a $11.00 price target on EPRX, signaling continued broker conviction and implying meaningful upside from current levels. Read More.
• Positive Sentiment: Lifesci Capital kept a “Strong-Buy” rating even as it adjusted estimates, which supports continued institutional optimism about the company’s longer-term prospects. Read More.
• Neutral Sentiment: HC Wainwright published a detailed multi-year forecast schedule (quarterly 2026 estimates and longer-term FY2030 view), providing updated guidance investors can use to re-model cash needs and valuation. Read More.
• Negative Sentiment: HC Wainwright cut near- and medium-term EPS estimates sharply: FY2026 from ($0.52) to ($0.96), FY2027 to ($0.91) (from $0.55 prior), FY2028 to ($1.05) (from ($0.63)), and FY2029 to ($0.42) (from ($0.13)). Those downgrades increase short-term downside risk and reflect a worse-than-expected path to profitability. Read More.
• Negative Sentiment: HC Wainwright trimmed its prior $12 price target to $11 (still a buy), signaling a modest reduction in their valuation uplift for the stock. Read More.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.